841 related articles for article (PubMed ID: 26721942)
1. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
3. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
[TBL] [Abstract][Full Text] [Related]
5. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
[TBL] [Abstract][Full Text] [Related]
7. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
[TBL] [Abstract][Full Text] [Related]
9. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
[TBL] [Abstract][Full Text] [Related]
10. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
12. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
[TBL] [Abstract][Full Text] [Related]
15. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
[TBL] [Abstract][Full Text] [Related]
18. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
19. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Jung YS; Park DI; Kim YH; Lee JH; Seo PJ; Cheon JH; Kang HW; Kim JW
J Gastroenterol Hepatol; 2015 Dec; 30(12):1705-12. PubMed ID: 25974251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
